drugset
drugset / Trial / NCT02388295

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

NCT02388295 ↗

Phase 2 Completed 59 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.

Timeline

Start
2015-04-27
Primary completion
2016-09-19
Completion
2016-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Verdiperstat Small molecule — Oral

Indications

multiple system atrophy